BS_0T17SY47
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 10.348226018396845
- age_years
- 23.074
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_2XD3MNKD | Glial-neuronal tumor NOS | — | 0.973 |
| 2 | MNG1280 | — | — | 0.971 |
| 3 | BS_CQSAJ7BF | DNET | — | 0.971 |
| 4 | MNG226 | — | — | 0.962 |
| 5 | BS_K5802F84 | pilocytic astrocytoma | — | 0.958 |
| 6 | BS_92VDQ0NE | Ganglioglioma | — | 0.957 |
| 7 | BS_QC3XCE6X | low-grade glioma | — | 0.956 |
| 8 | MNG700 | — | — | 0.953 |
| 9 | MNG540 | — | — | 0.952 |
| 10 | BS_JXNZYGCR | DNET | — | 0.951 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.425 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.367 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.148 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.143 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.064 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.053 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |